Cefepime

Posted on November 15, 2007 by Blake Bailey
FDA issued an early communication about new safety information and the request for additional data concerning  the risk of death in patients treated with cefepime. The May 2007 issue of The Lancet Infectious Diseases (Efficacy and safety of cefepime: a systematic review and meta-analysis) reported the increased mortality with the use of cefepime, a broad spectrum B-lactam antibiotic currently approved for the treatment of a variety of infections due to susceptible strains of microorganisms. The article describes a higher all-cause mortality in patients treated with cefepime compared to other B-lactam antibiotics. If someone has been prescribed this drug, I recommend that they contact their treating physician to discuss this breaking news.
Read the complete MedWatch 2007 Safety Summary including a link to the Early Communication Sheet regarding this ongoing safety review at:
http://www.fda.gov/medwatch/safety/2007/safety07.htm#Cefepime


http://www.bailey-law.com/lawyer-attorney-1215852.html

 
Tags: , , ,
Trackbacks (0) Links to blogs that reference this article Trackback URL
http://www.txinjurylawblog.com/admin/trackback/51459
Comments (0) Read through and enter the discussion with the form at the end
Post A Comment / Question Use this form to add a comment to this entry.







Remember personal info?
Send To A Friend Use this form to send this entry to a friend via email.